Evaluation of BTLA (CD272) Immune Checkpoint Levels Related to Hepatitis B virus Infection in Diabetes Mellitus Patients
DOI:
https://doi.org/10.46966/msjar.v5i1.173Keywords:
Anti-HBc IgG, BTLA, Diabetes mellitus, Hepatitis B virus, Immune checkpoints.Abstract
Background: Diabetes mellitus is a persistent disorder characterized by an imbalance in the regulation of glucose levels in the body. Hepatitis B is a hepatotropic virus that may trigger viral hepatitis, cirrhosis, and hepatocellular carcinoma. The B and T lymphocyte attenuator (BTLA/CD272) is a co-inhibitory receptor present in T lymphocytes and B lymphocytes. It plays a crucial role in controlling the activation of lymphocytes during periods of inflammation and infection. BTLA has high levels of expression in T-cells that are particular to the virus, resulting in a strong inhibitory impact on processes such as T-cell proliferation and cytokine release. Objective: The study aims to assess BTLA levels in relation to HBV infection in diabetes mellitus patients. Subjects and methods: A cross-sectional study was conducted from July to October 2023. The serum was obtained from 200 diabetics. All of the patients were tested using an ELISA technique for BTLA and HBc IgG. They were tested using a five-panel kit for HBsAb, HBsAg, HBcAb, HBeAg, and HBeAb. The statistical analysis approach was conducted using SPSS version 26. Results: Serum BTLA levels were correlated with serum HBc IgG positivity (P = 0.043) and total HBc Ab positivity (P = 0.017). There was no correlation between BTLA levels and serum HBs Ab (P = 0.151) or HBe Ab (p = 0.941). BTLA levels were not correlated with diabetes mellitus (P = 0.786). Conclusions: Elevated levels of BTlA in diabetic individuals who are exposed to the hepatitis B virus compared to those without this virus.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Baneen abdul Hadi Al-Hamdani, Saif Jabbar Yasir Al-Mayah
This work is licensed under a Creative Commons Attribution 4.0 International License.
In submitting the manuscript to the Medical Science Journal for Advance Research, the authors certify that:
- They are authorized by their co-authors to enter into these arrangements.
- The work described has not been formally published before, except in the form of an abstract or as part of a published lecture, review, thesis, or overlay journal.
- That it is not under consideration for publication elsewhere,
- The publication has been approved by the author(s) and by responsible authorities – tacitly or explicitly – of the institutes where the work has been carried out.
- They secure the right to reproduce any material that has already been published or copyrighted elsewhere.
- They agree to the following license and copyright agreement.
License and Copyright Agreement
Authors who publish with Medical Science Journal for Advance Research agree to the following terms:
- Authors retain copyright and grant the Medical Science Journal for Advance Research right of first publication with the work simultaneously licensed under Creative Commons Attribution License (CC BY 4.0) that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the Medical Science Journal for Advance Research published version of the work (e.g., post it to an institutional repository or edit it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) before and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
